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Abstract
Prior glaucoma severity staging systems were mostly concerned with visual
field function and retinal nerve fiber layer, but did not include intraocular
pressure or medications to capture resistance to treatment. We recently
introduced a simple index that combines pressure, medications, and visual field
damage and applied it to stratify outcomes of trabectome surgery. In the
analysis presented here, we combined data of trabectome alone and
trabectome with same session cataract surgery to increase testing power and
chances of effect discovery. This microincisional glaucoma surgery removes
the primary resistance to outflow in glaucoma, the trabecular meshwork, and
has been mostly used in mild glaucoma. Traditional glaucoma surgeries have a
relatively high complication rate and have been reserved for more advanced
disease stages. In the analysis presented here we include our data of
trabectome combined with cataract surgery. This is a common practice pattern
as both occur in the same age group with increasing frequency. For patients in
higher glaucoma index (GI) groups, the intraocular pressure (IOP) reduction
was 2.34+/-0.19 mmHg more than those in a GI group one level lower while
holding everything else constant. Those who had undergone trabectome
combined with phacoemulsification had an IOP reduction that was 1.29+/-0.39
mmHg less compared to those with trabectome alone. No statistically
significant difference was found between genders and age groups while
holding everything else constant. Hispanics had a 3.81+/-1.08 mmHg greater
IOP reduction. Pseudoexfoliation and steroid glaucoma patients had an IOP
reduction that was greater by 2.91+/-0.56 and 3.86+/-0.81 mmHg, respectively,
than those with primary open angle glaucoma. These results suggest a role for
trabectome-mediated ab interno trabeculectomy beyond mild forms of
glaucoma. Additionally, the multifactorial glaucoma index demonstrates a role
in staging patients when comparing glaucoma surgical modalities.
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            Amendments from Version 1
We have completely rewritten the Introduction to better explain 
the purpose of combining trabectome and phaco-trabectome 
data and the idea behind the glaucoma index – and explained 
the index in more detail in the Methods. In the Discussion we 
have expanded on the limitations of the study and added a better 
explanation why phaco-trabectome patients have a lesser IOP 
reduction 
See referee reports
REVISED
Introduction
Due to an increasing human lifespan, chronic diseases that 
manifest later in life, such as glaucoma and cataracts, have an 
increasing incidence and often occur in the same individuals1. 
Medications2 and surgeries3 for glaucoma can induce or worsen 
cataracts. As a results, combining both cataract and glaucoma 
surgery is increasingly common, especially since the introduction of 
safer, microincisional glaucoma surgeries4,5. We recently examined 
the amount of intraocular pressure (IOP) reduction due to phacoe-
mulsification at the time of trabectome surgery and found this to be 
clinically relatively insignificant6. We also noted that trabectome 
surgery performed after failed trabeculectomy caused patients with 
more advanced visual field damage to have on average a greater 
pressure and medication reduction despite similar medications7. In 
the current study we have consequently combined data of trabec-
tome and phaco-trabectome surgery patients and stratified them by 
a glaucoma severity index. The idea behind developing a glaucoma 
index was to twofold: 1) to control for different indications for 
surgery and 2) to stratify outcomes by glaucoma severity.
Because indications for surgery may be a reduction of IOP, 
elimination of medications, or vision improvement either alone 
or, more commonly, a combination of those, we recently created 
a simple glaucoma index8 that combines IOP, number of medica-
tions and visual field status to gauge relative clinical glaucoma 
severity but also describes resistance to treatment. Combining IOP 
and number of medications controls for treatment patterns. For 
instance, because glaucoma eye drops reduce IOP, a patient with 
an IOP of 16 mmHg on one medication might have a glaucoma 
that is clinically similarly challenging as one with an IOP of 
24 mmHg off treatment. 
Plasma-mediated ab interno trabeculectomy with the trabectome, 
the surgery examined here, removes the nasal trabecular meshwork 
(TM) that is thought to be the primary outflow resistance in glau-
coma9. However, more recent insight has demonstrated a significant 
contribution by unidentified elements downstream of the trabecular 
meshwork6,7,10 as half of the outflow resistance might remain unac-
counted for11,12. Since removal of TM is achieved in all patients 
regardless of glaucoma severity, outcome differences have to reflect 
differences in the outflow tract distal to the TM. We included the 
visual field status to investigate whether IOP reduction from trabec-
tome surgery might be correlated to glaucoma severity. By com-
bining both trabectome and phaco-trabectome surgery data, a more 
complete picture can be obtained to guide surgeons on whether ab 
interno trabeculectomy may be an appropriate primary intervention.
Methods
This retrospective analysis was approved (PRO14100026) by 
the Institutional Review Board of the University of Pittsburgh in 
accordance with the Declaration of Helsinki and the Health Insur-
ance Portability and Accountability Act. Because of the retro-
spective nature, no consent was required. Glaucoma patients who 
received trabectome with or without phacoemulsification were 
enrolled, except in the following circumstances: history of glau-
coma surgery, any subsequent cataract or glaucoma surgery in the 
follow-up period, and short term followup (less than 12 months). 
A history of laser trabeculoplasty did not lead to exclusion. Patients 
were divided into four groups (from mild to severe) according to 
a glaucoma index (GI), an indicator of glaucoma severity based 
on visual field, number of glaucoma medications, and preopera-
tive IOP8. Baseline IOP was divided into 4 groups, <20 mmHg, 
20–29 mmHg, 30–39 mmHg, and above 40 and assigned with 
1 to 4 points. Glaucoma medications (meds) were divided into 
4 groups: ≤1, 2, 3, or ≥4, and assigned values of 1 to 4. Visual 
field (VF) was separated into 4 groups with points from 1 to 4: 
mild, moderate, advanced and end stage. GI was then defined as 
VF*meds*IOP and separated into GI group 1 = mild, GI group 
2 = moderate, GI group 3 = advanced, and GI4 = severe defined 
based on glaucoma index scores of “≤4”, “4<;GI≤8”, “8<GI≤16”, 
and “>16,” respectively. The main outcome measure was the reduc-
tion of IOP. Secondary outcome measures included reduction of 
medication and a Kaplan-Meier survival analysis. Baseline char-
acteristics were analyzed by the Kruskal-Wallis and chisquare 
tests for continuous and categorical variables between GI groups, 
respectively. Univariate linear regression was performed first 
and those demographics found to be statistically significant were 
included into the multivariate regression analysis. Kaplan-Meier 
was used for survival-curve analyses. Surgical success was defined 
as IOP≤21 mmHg or at least 20% IOP reduction from baseline in 
any two consecutive visits after three months and no secondary 
glaucoma surgery. Log-rank test was used to compare survival 
distributions of GI groups.
Results
A total of 1340 cases of glaucoma patients were enrolled in the 
study and most of them were primary open angle glaucoma (POAG). 
The distribution across glaucoma severity groups was relatively 
even in number and average ages (Table 1). There was a slight pre-
ponderance of female patients in the mild and moderate groups. 
The ethnicity of most patients was Caucasian followed by Asian. 
POAG and pseudoexfoliation glaucoma were the most common 
diagnoses. The cup disc ratio increased by glaucoma index group 
and more patients were phakic than pseudophakic. More patients 
in the higher GI groups had a trabectome surgery that was com-
bined with cataract surgery. Patients with a higher GI group had 
a more profound IOP reduction (Figure 1). At one year, the mean 
IOP reduction was 3.57±5.01, 5.34±5.40, 7.75±7.40, 12.09±8.08 
mmHg for GI group 1 to 4, respectively. This pressure decrease 
occurred already on day 1 and remained relatively stable (Figure 2). 
Similarly, patients with more severe glaucoma experienced a 
larger reduction in medications which were tapered more gradu-
ally (Figure 3). When we stratified the overall IOP reduction by 
glaucoma severity, patients with worse glaucoma had the largest 
decrease.
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Table 1. Demographics. Glaucoma index (GI); GI1 Mild: GI≤4; GI2 Moderate: 4<GI≤8; GI3 
Advanced: 8<GI≤16; GI4 Severe: GI>16.
GI Group 1 
n=368
GI Group 2 
n=322
GI Group 3 
n=370
GI Group 4 
n=280 p-value
Age 0.02
  Mean±SD 71±11 68±13 69±15 66±18
  Range 18 – 92 18 – 90 18 – 96 18 – 96
Gender <0.01
  Female 225 (61%) 181 (56%) 183 (49%) 135 (48%)
  Male 139 (38%) 139 (43%) 184 (50%) 136 (49%)
  NR 4 (1%) 2 (1%) 3 (1%) 9 (3%)
Race <0.01
  African American 29 (8%) 16 (5%) 17 (5%) 14 (5%)
  Asian 98 (27%) 86 (27%) 115 (31%) 107 (38%)
  Caucasian 203 (55%) 177 (55%) 202 (55%) 124 (44%)
  Hispanic 23 (6%) 16 (5%) 17 (5%) 21 (8%)
  Other 15 (4%) 27 (8%) 19 (5%) 14 (5%)
Glaucoma Diagnosis <0.01
  Primary open angle 288 (78%) 241 (75%) 257 (69%) 179 (64%)
  Pseudoexfoliation 28 (8%) 37 (11%) 59 (16%) 41 (15%)
  Pigment Dispersion 18 (5%) 10 (3%) 11 (3%) 6 (2%)
  Steroid 10 (3%) 18 (6%) 28 (8%) 39 (14%)
  Open angle type not 
specified 24 (7%) 16 (5%) 15 (4%) 15 (5%)
Visual Acuity (logMAR) <0.01
  Mean±SD 0.31±0.34 0.28±0.35 0.37±0.52 0.47±0.61
  Range -0.19 – 2.12 -0.19 – 2.00 -0.19 – 3.00 -0.19 – 3.00
Cup/Disc Ratio <0.01
  Mean±SD 0.69±0.18 0.74±0.15 0.75±0.17 0.83±0.12
  Range3 0.1 – 1.9 0.3 – 1.00 0.1 – 1.00 0.25 – 1.00
Lens Status <0.01
  Phakic 296 (80%) 231 (72%) 240 (65%) 159 (57%)
  Pseudophakic 56 (15%) 78 (24%) 116 (31%) 104 (37%)
  Aphakic 1 (0%) 1 (0%) 0 (0%) 3 (1%)
  Not recorded 15 (4%) 12 (4%) 14 (4%) 14 (5%)
Shaffer Grade 0.47
  I 5 (1%) 6 (2%) 4 (1%) 2 (1%)
  II 23 (6%) 25 (8%) 20 (5%) 27 (10%)
  III 107 (29%) 99 (31%) 121 (33%) 85 (30%)
  IV 192 (52%) 146 (45%) 172 (46%) 134 (48%)
  NR 41 (11%) 46 (14%) 53 (14%) 32 (11%)
Combined Surgeries <0.01
  Trabectome+Phaco 164 (45%) 202 (63%) 260 (70%) 216 (77%)
  Trabectome Alone 204 (55%) 120 (37%) 110 (30%) 64 (23%)
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Figure 2. Intraocular pressure over time by glaucoma index group. Patients with a higher group had the largest decrease (average and 
standard deviation).
Figure 1. Reduction of intraocular pressure at 1 year. More severe glaucoma was associated with a larger pressure reduction.
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Table 2. Univariate regression.
Coefficient Standard Error p-value
Age -0.06 0.02 <0.01
Male 1.12 0.40 0.01
Ethnicity 
  Asian 0.45 0.90 0.61
  Caucasian 0.12 0.87 0.89
  Hispanic 4.45 1.16 <0.01
  Other -0.57 1.26 0.66
Diagnosis 
  Open angle type not 
specified 0.78 0.90 0.39
  Pigmentary Dispersion 0.41 1.12 0.71
  Pseudoexfoliation 
Glaucoma 3.44 0.59 <0.01
  Steroid Glaucoma 5.38 0.88 <0.01
Cup/Disc Ratio -2.30 1.34 0.09
Shaffer Grade -0.38 0.31 0.21
Lens 
  Aphakic 0.59 3.10 0.85
  Pseudophakic 0.66 0.49 0.18
Combined with phaco -3.20 0.41 <0.01
Figure  3. Medications  by  glaucoma  index  group. Patients in the severe and advanced groups had the largest medication reduction 
(average and standard deviation).
In the univariate regression analysis, age was slightly negatively 
correlated with the amount of IOP reduction (Table 2) but this was 
not noted in the multivariate regression (Table 3) while male gen-
der had a positive correlation in the univariate but not anymore in 
the multivariate regression. For patients in the higher GI group, the 
IOP reduction was 2.34±0.19 mmHg more than those in one level 
lower GI group while holding everything else constant. Hispanics 
experienced a pressure drop larger by 3.81±1.08 mmHg than other 
ethnicities as did patients with a diagnosis of pseudoexfoliation 
and steroid induced glaucoma (Table 3). IOP reduction was 
2.91±0.56 and 3.86±0.81 mmHg more than in POAG patients. 
Interestingly, cataract surgery was associated with a slightly worse 
IOP reduction by 1.29+/-0.39 mmHg (Table 3).
Survival rate at 12 months was 93%, 84%, 82% and 74% for GI 
group 1 to 4 (Figure 4). Log-rank test indicated statistically signif-
icant differences between the GI groups and patients in the lower 
GI groups had a higher survival rate than those in higher GI 
groups.
Discussion
The results of the current study are confirmatory of our prior study 
where we examined the impact of a glaucoma severity index on 
the results of trabectome surgery when done as a standalone pro-
cedure14. The larger number of patients involved here allowed dis-
covery of additional factors. We included here phaco-trabectome 
patients, who have a different, mixed indication that often includes 
visually significant cataract as the primary motivator while 
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presenting with a relatively stable glaucoma. without the need for 
pressure reduction but a motivation to reduce medications. We did 
so after demonstrating by a rigorous statistical matching method, 
coarsened exact matching13, that phacoemulsification does not 
contribute significantly to IOP reduction when done at the same 
time6 or in a surgery prior to trabectome surgery14. As in our prior 
studies14, phaco-trabectome patients had a lower preoperative IOP. 
This study focused on stratification of outcomes by glaucoma index 
and did not apply advanced matching strategies that we applied 
elsewhere6,14,15 to compare two groups. Hence, one cannot con-
clude from this study that cataract surgery is causatively linked to 
a diminished IOP reduction when compared to trabectome-only 
patients. On the contrary, an IOP reduction in many of our 
phaco-trabectome patients is simply not necessary to the same 
degree.
The results of this study match established risk factors and findings 
from other studies. Steroid glaucoma and pseudoexfoliation often 
produce very high IOPs and the primary pathology is located in the 
trabecular meshwork. As a result, ablating the meshwork reduces 
intraocular pressure very effectively17.
In that study we found that a larger pressure reduction is achieved 
in more severe glaucoma consisting of a more advanced visual field 
damage, a higher pre-intervention IOP and more medications. We 
Table 3. Multivariate Regression.
Coefficient Standard Error p-value
Glaucoma index 
group  2.34 0.19 <0.01
Age  -0.02 0.02 0.11
Male  0.60 0.38 0.12
Ethnicity 
  Asian -0.57 0.84 0.50
  Caucasian 0.10 0.84 0.90
  Hispanic 3.81 1.08 <0.01
  Other -0.30 1.05 0.78
Diagnosis 
  Open angle type 
not specified 1.30 0.79 0.10
  Pigmentary 
Dispersion 0.54 1.10 0.62
  Pseudoexfoliative 
Glaucoma 2.91 0.56 <0.01
  Steroid Glaucoma 3.86 0.81 <0.01
Combined with 
phaco  -1.29 0.39 <0.01
Figure 4. Survival plot by GI groups. The highest GI group with more advanced glaucoma (GI4, red) had the worst survival.
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had previously found that cup disc ratio, Hispanic ethnicity and 
diagnosis of steroid-induced glaucoma are related to a larger IOP 
reduction14. In addition to steroid induced glaucoma, pseudoex-
foliation glaucoma confers a larger IOP reduction in the present 
study. Although phacoemulsification was negatively correlated with 
IOP reduction in this analysis, something that has been described 
for combined traditional trabeculectomy18,19, it is important to recall 
that this study was not designed to formally compare outcomes of 
combined versus trabectome-alone as we have done before9. The 
number of patients analyzed here is significantly higher than in the 
two separate studies but we note similar results in the regression 
analysis allowing to discover additional factors.
The Goldmann equation describes that the limiting factor to IOP 
reduction after removal of the trabecular meshwork, the substrate 
of the main outflow resistance, is the episcleral venous pressure 
and uveoscleral outflow11. The data presented here indicate that that 
this is mostly true also for more advanced glaucoma and consist-
ent with two prior studies that demonstrated that significant con-
ventional outflow can be recovered even after failed tube shunts20 
and after failed trabeculectomy10. Small differences of the eventu-
ally achieved pressures could be explained by an episcleral venous 
pressures that is higher in glaucoma12. This study has several 
limitations: to maximize patient number, we included all trabec-
tome surgeries regardless of lens status or lens-cosurgery because 
our prior studies indicated that neither had a clinically relevant 
impact14,22,23. This study was limited to only one year when follow 
up and data integrity was most amenable to automated retrieval 
and analysis. As a retrospective analysis, this study cannot dis-
cover causality and is only able to advise that patients with more 
severe glaucoma had a similar postoperative IOP and a comparable 
reduction in medications as those with mild glaucoma. Overall, the 
data presented here suggest that ab interno trabeculectomy might 
be an appropriate surgery to attempt to control more than mild 
glaucoma.
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 Steven R. Sarkisian Jr.
University of Oklahoma College of Medicine, Oklahoma City, OK, USA
This is an interesting study demonstrating that ab interno trabeculectomy is an appropriate surgery to
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This is an interesting study demonstrating that ab interno trabeculectomy is an appropriate surgery to
attempt to control more than mild glaucoma. Ab interno trabeculotomy is a growing trend in glaucoma
surgery, not just with the trabectome device, but also with the dual blade that is recently on the market
from New World Medical, and also the Sight Sciences device called TRAB 360. The trend toward ab
interno, non-penetrating surgery in patients with not only mild, but even advanced glaucoma
demonstrates our aversion for conventional filtration surgery and the significantly high complication rate
seen with it. I am grateful to the authors for writing up their large case series of results that mirror a "real
world" practice using this procedure. Glaucoma surgeons need to consider expanding the use of this type
of technique, knowing that by doing so, they do not rule out the possibility of doing conventional surgery in
the future, if necessary.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 Dr Sarkisian is a consultant to New World Medical, Sight Sciences, Beaver VistecCompeting Interests:
International, Glaukos, Alcon, Aeon Astron, and InnFocus. He has received research funding from
Glaukos, Transcend, and Aeon Astron.
 13 May 2016Referee Report
doi:10.5256/f1000research.9096.r13591
 William Myers
Department of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
The concept of creating glaucoma index buckets has been validated by the authors in their 
paper .  They showed that similar patients with and without cataract undergoing ab-internoPLoS One 
trabeculectomy can be combined in one study. I found the conclusion that use of the Trabectome would
be potentially useful in many cases of procedures combined with cataract surgery, even when the
glaucoma is fairly far advanced. As the site of greatest resistance to fluid exit, removing the trabecular
membrane alone could potentially lower a high enough pressure gradient, at least temporarily. With the
potential to avoid a full thickness filter and its attendant complications, the Trabectome could buy time to
ride out a post operative cataract pressure spike.
I would like to see more analysis of when an ab-interno trabeculectomy might be risky such as in severe
glaucoma with split fixation where the alternative is an ab-externo filter or tube and then later cataract
surgery. If this procedure is more effective than iStent and other bypass procedures, and involves no
costly per case costs in comparison, then Trabectome with phacoemulsification may be the most prudent
choice.
.  
At the other end of the spectrum in ocular hypertension patients with no current measurable
damage, is the risk profile of Trabectome combined with phacoemulsification reasonable, compared to
the risk and cost of drops or SLT as alternatives? We know that the effectiveness of only one iStent, the
FDA approved norm in the US, is quite often not sufficient to reduce pressures adequately.
There was another issue to be considered. The grading system uses pressure as one of the components
and also uses the pressure drop as the metric of success. There be some circular reasoning involved,
as the initial pressure head itself is a determinant of the resulting pressure drop using drops,
lasers or surgery. Unfortunately the study can not be replicated exactly due to patient confidentiality
1
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lasers or surgery. Unfortunately the study can not be replicated exactly due to patient confidentiality
considerations.
The validated glaucoma severity scale. from their previous paper in PLoS, uses simple-to-obtain inputs:
IOP, number of medications and visual field loss; graded using MD and PSD from the visual field testing.
The combination of these factors with definable numeric values can be utilized by cataract surgeons
without glaucoma subspecialties.
References
1. Loewen RT, Roy P, Parikh HA, Dang Y, Schuman JS, Loewen NA: Impact of a Glaucoma Severity
Index on Results of Trabectome Surgery: Larger Pressure Reduction in More Severe Glaucoma.PLoS
. 2016;  (3): e0151926  |  One 11 PubMed Abstract Publisher Full Text
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
Author Response 09 Jun 2016
, Nils Loewen
I would like to see more analysis of when an ab-interno trabeculectomy might be risky such as in
severe glaucoma with split fixation where the alternative is an ab-externo filter or tube and then
later cataract surgery. If this procedure is more effective than iStent and other bypass procedures
and involves no costly per case costs in comparison, then Trabectome with phacoemulsification
may be the most prudent choice.
This study is designed to analyze how patients with more severe glaucoma fared duringAuthors: 
the one-year follow-up, and the all-inclusive design maximizes the patient numbers. The results
indicate that this microincisional surgery is a viable first option even in more severe glaucoma for
many patients, but the resulting pressure is not low enough for many as the survival curve
demonstrates. Postoperative complications are surprisingly common after traditional glaucoma
surgery. Leakage, endophthalmitis, hypotony,  hardware erosion, damage to ocular tissues and
other complications that are vision threatening occur with an additive probability of 77% in
trabeculectomies and 58% in glaucoma drainage implants.  The surgeon has to discuss with each
patient whether the avoidance of postoperative complications of traditional surgeries is worth the
risk of an insufficient pressure reduction and the need to move on. In this context, it is important to
recall that the postoperative IOP for tubes and trabeculectomies is only approximately 1 to 2 mmHg
less that reported here.
In forthcoming publications with fewer patients and full data disclosure, we report propensity score
matched results of tube shunts and trabectome for a valid comparison of these surgical modalities.
Because of the speed and safety of ab interno trabeculectomy, there is also a role for combining
the two to achieve a lower IOP with fewer medications.
At the other end of the spectrum in ocular hypertension patients with no current measurable
damage, is the risk profile of Trabectome combined with phacoemulsification reasonable,
compared to the risk and cost of drops or SLT as alternatives? We know that the effectiveness of
only one iStent, the FDA approved norm in the US, is quite often not sufficient to reduce pressures
adequately.
9
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only one iStent, the FDA approved norm in the US, is quite often not sufficient to reduce pressures
adequately.
It is hard to compare the effectiveness of different surgeries and in various practicesAuthors: 
without a randomized controlled design. The only way to obtain a high-quality comparison is to
perform matching as we have done recently.  A cost analysis is similarly specific to
the geographical area and practice. Prior cost analyses suggest that SLT is better or similar to eye
drops in lowering IOP and more cost effective, even returning more than initially invested.  The
same can be said about micro-incisional glaucoma surgeries  although this depends on the
long-term viability of the chosen surgical modality and costs of anesthesia. SLT is our first line of
treatment before use of drops and trabectome surgery presents a sharp step up. It is certainly
convenient, fast and safe to combine at the time of cataract surgery. After trabectome surgery, only
the distal outflow tract generates pressure causing most patients to drop into the mid-teens while
SLT achieves more of a relative reduction that depends on the preoperative IOP. Our study
presented here shows that the postoperative results are mostly independent of preoperative IOP
(or that a larger IOP reduction is achieved in higher preoperative IOP).
There was another issue to be considered. The grading system uses pressure as one of the
components and also use s the pressure drop as the metric of success. There be some circular
reasoning involved, as the initial pressure head itself is a determinant of the resulting pressure drop
using drops, lasers or surgery.
Different from other glaucoma staging systems graded by a defect of visual field or opticAuthors: 
nerve injury , the glaucoma index here includes the relative resistance to treatment by
individual patients. There is no circular logic, however, because we did not develop a prediction
model that would have used a set of normal patients to train an algorithm and control patients
within a study that were separated out from progressing patients as we have used elsewhere .
Both IOP and medications are reduced (or one could say the glaucoma index is reduced) by this
procedure.  
Unfortunately the study can not be replicated exactly due to patient confidentiality considerations.
 HIPAA concerns are particularly relevant for this study describing many individuals.Authors:
Fines can quickly climb to millions of dollars: 
 We are veryhttps://www.truevault.com/blog/what-is-the-penalty-for-a-hipaa-violation.html
impressed with F1000Research and the compelling benefits of pre-printing and open peer review
and will provide full open data with our upcoming publications. Although it is the standard not to
release full datasets in clinical ophthalmology publications, we have come to realize that this is a
disservice. For instance, one could apply matching strategies to other datasets to compare
surgeries and we hope to make ours available for this purpose.
The validated glaucoma severity scale from their previous paper in PLoS, uses simple-to-obtain
inputs: IOP, the number of medications and visual field loss graded using MD and PSD from the
visual field testing. The combination of these factors with definable numeric values can be utilized
by cataract surgeons without glaucoma subspecialties.
 Yes, we agree. We were surprised that this has not been attempted before. Hopefully,Authors:
better indices will become available. We have a glaucoma risk calculator in our medical record
system, a customized version of Epic, and that has been a big step forward.
 References used in this Reply to Reviewers
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 Kristy G. Mascarenhas
Hartford Hospital/Middlesex Hospital, Middletown, CT, USA
This was an interesting analysis of the use of Trabectome surgery in patients with more severe
glaucomas. Comments and questions are as follows, most of which would clarify the methods and data
analysis for the reader:
The abstract and introduction could be clearer about the purpose of the study.  You have to wait a
long time to find out that this was a retrospective chart review of patients who had received
Trabectome and phaco-Trabectome surgeries.  Were the authors looking for statistically significant
differences in IOP reduction between the glaucoma severity groups, or equivalent effect in mild vs.
severe glaucoma?  If so, was a power calculation done?
 
The abstract makes it sound as though only phaco-Trabectome cases were included, but the
introduction states that both Trabectome and combined surgeries were included. Please clarify the
abstract?
 
The methods section briefly introduces the glaucoma index system that was used, but especially
for someone who has not read the previous article evaluating it, a bit more detail about the point
system used would be helpful.
 
One of the exclusion criteria was prior glaucoma surgery. Is data available about the number of
patients who had previously had SLT/ALT?
 
Table 1 shows the number of Trabectomes vs. phaco/Trabectomes. Did all phakic patients have
cataract surgery, or did any receive Trabectome alone?
 
Over what time period did the reviewed patients receive Trabectome? Relatively recently, or closer
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Over what time period did the reviewed patients receive Trabectome? Relatively recently, or closer
to the beginning of Trabectome use? How many different surgeons' patients were reviewed? (Is it
possible that surgical techniques evolved over time, or that different surgeons' techniques varied
significantly?)  A sentence like "We reviewed the charts of XXX patients from XXX surgeons who
underwent CE/Trabectome or Trabectome alone between 2012-2016" would be very helpful.
 
The authors state that patients in the severe GI group and patients with more severe glaucomas
like pseudoexfoliation and steroid-response had a greater IOP reduction than other groups. Since
IOP is one component of the glaucoma index and Trabectome does lower IOP more significantly
with higher pre-op IOP, is it possible to say that Trabectome had a greater effect in these groups
independently of pre-op IOP? (To confirm, was this analysis done?)
 
Can the authors include a short discussion of limitations of the current study and possibly a bit of
speculation on the smaller IOP reduction with phaco/Trabectome than with Trabectome alone, as
well as on why the more severe GI groups saw a shorter-lived IOP reduction?
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
Author Response 09 Jun 2016
, Nils Loewen
This was an interesting analysis of the use of Trabectome surgery in patients with more severe
glaucomas. Comments and questions are as follows, most of which would clarify the methods and
data analysis for the reader: The abstract and introduction could be clearer about the purpose of
the study.  You have to wait a long time to find out that this was a retrospective chart review of
patients who had received Trabectome and phaco-Trabectome surgeries.
Were the authors looking for statistically significant differences in IOP reduction between the
glaucoma severity groups, or equivalent effect in mild vs. severe glaucoma?  
If so, was a power calculation done?
 Thank you for the opportunity to revise our abstract and introduction.Authors:
We have added to the abstract: “In the analysis presented here, we combined data of trabectome
alone and trabectome with same session cataract surgery to increase testing power and chances
of effect discovery.”
We have also completely rewritten the introduction to explain  the purpose of combining
trabectome and phaco-trabectome data better and the idea behind the glaucoma index. Briefly, we
recently created a simple glaucoma index that combines IOP, the number of medications and
visual field status to gauge relative clinical glaucoma severity but also describes resistance to
treatment. This may control for medication use when trying to gauge IOP results and allow to focus
on glaucoma severity related outcomes. We combined trabectome and phaco-trabectome data
sets because phacoemulsification is not a significant contributor to IOP reduction in studies with
advanced matching strategies.
A power calculation was done and our regression analysis has a power of 0.95.  We would require
82 patients to detect a GI IOP difference for a medium sized effect of 0.3 and a power of 80%. As
our statistician advises, a power analysis is only needed when no statistical significance is found
and that is why we had not reported it in our original submission. If a statistically significant
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and that is why we had not reported it in our original submission. If a statistically significant
difference is found as here, then that suggests that the statistical test is powerful enough.
The abstract makes it sound as though only phaco-Trabectome cases were included, but the
introduction states that both Trabectome and combined surgeries were included. Please clarify the
abstract?
 Thank you for noticing this. Both were included and we have added the following to theAuthors:
abstract: “In the analysis presented here, we combined data of trabectome alone and trabectome
with same session cataract surgery to increase testing power and chances of effect discovery.”
The methods section briefly introduces the glaucoma index system that was used, but especially
for someone who has not read the previous article evaluating it, a bit more detail about the point
system used would be helpful.
 We have updated our methods section to explain the individual factors in more detail:Authors:
“Patients were divided into four groups (from mild to severe) according to a glaucoma index (GI),
an indicator of glaucoma severity based on visual field, the number of glaucoma medications, and
preoperative IOP . Baseline IOP was divided into 4 groups, <20 mmHg, 20-29 mmHg, 30-39
mmHg, and above 40 and assigned with 1 to 4 points. Glaucoma medications (meds) were divided
into 4 groups: ≤1, 2, 3, or ≥4, and assigned values of 1 to 4. Visual field (VF) was separated into 4
groups with points from 1 to 4: mild, moderate, advanced and end-stage. GI was then defined as
VF*meds*IOP and separated into GI group 1 = mild, GI group 2 = moderate, GI group 3 =
advanced, and GI4 = severe defined based on glaucoma index scores of “≤4”, “4<GI≤8”,
“8<GI≤16”, and “>16,” respectively.”
One of the exclusion criteria was prior glaucoma surgery. Is data available about the number of
patients who had previously had SLT/ALT?
Authors: Laser trabeculoplasty is the first line of treatment in our practice pattern, and this was not
an exclusion criterion. Nearly all patients will have had this. Trabeculoplasty was not included as a
factor in the analysis to reduce complexity. We have added to Methods: “A history of laser
trabeculoplasty did not lead to exclusion.”
Table 1 shows the number of Trabectomes vs. phaco/Trabectomes. Did all phakic patients have
cataract surgery, or did any receive Trabectome alone?
We have analyzed the effect of trabectome in phakic patients before in two differentAuthors: 
studies  and found that even in narrow angles there does not seem to be a significant difference.
Consequently, we included here all patients, including trabectome patients who remained phakic,
to focus on the glaucoma index without further break down into subgroups.
It is important to recall that differences in phaco versus no phaco are merely based on averages.
Because of a mixed indication for these patients (many cataract surgery patients do not need a
pressure reduction and merely want to reduce medications) and because no formal matching was
done, one cannot conclude from this study that cataract surgery is causatively linked to a
diminished IOP reduction when compared to trabectome-only patients. On the contrary, an IOP
reduction in many of our phaco-trabectome patients is simply not necessary to the same degree.
Over what time period did the reviewed patients receive Trabectome? Relatively recently, or closer
to the beginning of Trabectome use? How many different surgeons' patients were reviewed? (Is it
1
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to the beginning of Trabectome use? How many different surgeons' patients were reviewed? (Is it
possible that surgical techniques evolved over time, or that different surgeons' techniques varied
significantly?)  A sentence like "We reviewed the charts of XXX patients from XXX surgeons who
underwent CE/Trabectome or Trabectome alone between 2012-2016" would be very helpful.
The study period included data from 2011 up until the end of 2015. We did not analyzeAuthors: 
outcomes by individual surgeons. We concede that a majority of surgeries was performed by the
senior author of this study and after 2012. Unfortunately, is not easily possible to provide the exact
breakdown due to how data is extracted from the EMR data cloud. Manual curation of thousands of
patient operative reports would be necessary.
the authors state that patients in the severe GI group and patients with more severe glaucomas like
pseudoexfoliation and steroid-response had a greater IOP reduction than other groups. Since IOP
is one component of the glaucoma index and Trabectome does lower IOP more significantly with
higher pre-op IOP, is it possible to say that Trabectome had a greater effect in these groups
independently of pre-op IOP? (To confirm, was this analysis done?)
Thank you very much for this inquiry. Without conducting a prospective, randomizedAuthors: 
controlled study or applying an advanced matching strategy, it is not possible to detect a strong,
likely causative, correlation between glaucoma type and the amount of resulting IOP drop. The
multivariate regression analysis we have done here does show that pseudoexfoliation and steroid
glaucoma are significantly associated with a larger IOP reduction. This would be expected since
both are obvious trabecular meshwork diseases. It is not clear what the substrate is that prevents
IOP from  reaching the theoretical limit of episcleral venous pressure after trabecular ablation or
bypass.
The glaucoma index already captures resistance to medical treatment and these eyes require an
IOP that is considerably lower than what can be achieved by trabecular ablation. This may reflect a
tipping point.
Can the authors include a short discussion of limitations of the current study and possibly a bit of
speculation on the smaller IOP reduction with phaco/Trabectome than with Trabectome alone, as
well as on why the more severe GI groups saw a shorter-lived IOP reduction?
Thank you. We would like to add to the discussion the following: “This study has severalAuthors: 
limitations: to maximize patient number, we included all trabectome surgeries regardless of lens
status or lens-cosurgery because our prior studies indicated that neither had a clinically relevant
impact.  This study was limited to only one year when follow-up and data integrity was most
amenable to automated retrieval and analysis. As a retrospective analysis, this study cannot
discover causality and is only able to advise that patients with more severe glaucoma had a similar
postoperative IOP and a comparable reduction in medications as those with mild glaucoma.”
We have also added a better explanation why phaco-trabectome patients have a lesser IOP
reduction: “We included here phaco-trabectome patients, who have a different, mixed indication
that often includes a visually significant cataract as the primary motivator while presenting with a
relatively stable glaucoma without the need for pressure reduction but a motivation to reduce
medications. We did so after demonstrating by a rigorous statistical matching method, coarsened
exact matching , that phacoemulsification does not contribute significantly to IOP reduction when
done at the same time  or in a surgery prior to trabectome surgery . As in our prior studies ,
phaco-trabectome patients had a lower preoperative IOP. This study focused on stratification of
4
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phaco-trabectome patients had a lower preoperative IOP. This study focused on stratification of
outcomes by glaucoma index and did not apply advanced matching strategies that we applied
elsewhere  to compare two groups. Hence, one cannot conclude from this study that cataract
surgery is causatively linked to a diminished IOP reduction when compared to trabectome-only
patients. On the contrary, an IOP reduction in many of our phaco-trabectome patients is simply not
necessary to the same degree.”
References used in this Reply to Reviewers
Loewen, R. T. et al. Impact of a Glaucoma Severity Index on Results of Trabectome
Surgery: Larger Pressure Reduction in More Severe Glaucoma. PLoS One 11, e0151926
(2016).
 
Bussel, I. I., Kaplowitz, K., Schuman, J. S., Loewen, N. A. & Trabectome Study Group.
Outcomes of ab interno trabeculectomy with the trabectome by degree of angle opening. Br.
J. Ophthalmol. 99, 914–919 (2015).
 
Parikh, H. A., Bussel, I. I., Schuman, J. S., Brown, E. N. & Loewen, N. A. Coarsened Exact
Matching of Phaco-Trabectome to Trabectome in Phakic Patients: Lack of Additional
Pressure Reduction from Phacoemulsification. PLoS One 11, e0149384 (2016).
 
Wollstein, G. et al. Retinal nerve fibre layer and visual function loss in glaucoma: the tipping
point. Br. J. Ophthalmol. 96, 47–52 (2012).
 
Neiweem, A. E., Bussel, I. I., Schuman, J. S., Brown, E. N. & Loewen, N. A. Glaucoma
Surgery Calculator: Limited Additive Effect of Phacoemulsification on Intraocular Pressure in
Ab Interno Trabeculectomy. PLoS One 11, e0153585 (2016).
 
Iacus, S. M., King, G. & Porro, G. Causal Inference without Balance Checking: Coarsened
Exact Matching. Polit. Anal. 20, 1–24 (2012).
 
Parikh, H. A., Bussel, I. I., Schuman, J. S., Brown, E. N. & Loewen, N. A. Coarsened Exact
Matching of Phaco-Trabectome to Trabectome in Phakic Patients: Lack of Additional
Pressure Reduction from Phacoemulsification. PLoS One 11, e0149384 (2016).
 
Akil, H. et al. Clinical Results of Ab Interno Trabeculotomy Using the Trabectome in Patients
with Pigmentary Glaucoma compared to Primary Open Angle Glaucoma. Clin. Experiment.
Ophthalmol. (2016). doi:10.1111/ceo.12737
 
Gedde, S. J. et al. in Am J Ophthalmol 153, 804–814.e1 (2012 Elsevier Inc, 2012).
 
Gedde, S. J. et al. Treatment Outcomes in the Tube Versus Trabeculectomy (TVT) Study
After Five Years of Follow-up. Am. J. Ophthalmol. 153, 789–803.e2 (2012).
 
Taylor, H. R. Glaucoma: where to now? Ophthalmology 116, 821–822 (2009).
 
Rein, D. B. et al. The cost-effectiveness of routine office-based identification and
5,7,8
Page 19 of 20
F1000Research 2016, 5:762 Last updated: 27 JUN 2016
F1000Research
12.  
13.  
14.  
15.  
16.  
17.  
Rein, D. B. et al. The cost-effectiveness of routine office-based identification and
subsequent medical treatment of primary open-angle glaucoma in the United States.
Ophthalmology 116, 823–832 (2009).
 
Iordanous, Y., Kent, J. S., Hutnik, C. M. & Malvankar-Mehta, M. S. Projected Cost
Comparison of Trabectome, iStent, and Endoscopic Cyclophotocoagulation Versus
Glaucoma Medication in the Ontario Health Insurance Plan. J. Glaucoma (2013). doi:
10.1097/IJG.0b013e31829d9bc7
 
Brusini, P. & Filacorda, S. Enhanced Glaucoma Staging System (GSS 2) for classifying
functional damage in glaucoma. J. Glaucoma 15, 40–46 (2006).
 
Mills, R. P. et al. Categorizing the stage of glaucoma from pre-diagnosis to end-stage
disease. Am. J. Ophthalmol. 141, 24–30 (2006).
 
Advanced Glaucoma Intervention Study. 2. Visual field test scoring and reliability.
Ophthalmology 101, 1445–1455 (1994).
 
Zhang, X. et al. Predicting Development of Glaucomatous Visual Field Conversion Using
Baseline Fourier-Domain Optical Coherence Tomography. Am. J. Ophthalmol. 163, 29–37
(2016).
 NAL has received honoraria for trabectome wet labs and lectures fromCompeting Interests:
Neomedix Corp.
Page 20 of 20
F1000Research 2016, 5:762 Last updated: 27 JUN 2016
